AUA 指南第二部分:肾脏肿块与局限性肾癌的积极监测及干预后随访
该 AUA 指南聚焦成人临床局限性肾脏肿块(含实性强化肿瘤及 Bosniak 3/4 复杂囊性病变)的积极监测(AS)与干预后随访。
要点
- 对 <2cm 实性强化肾肿块或 predominantly 囊性 Bosniak 3-4 病变可考虑 AS 并可能延迟干预。
- AS 决策需共享决策,权衡干预风险/竞争性死亡与潜在肿瘤学获益。
- 干预后采用基于风险的随访方案,选择性使用实验室与影像资源。
核心结论
- AS 是部分临床局限性肾肿块患者的潜在管理策略,需仔细风险评估、共享决策和定期再评估。
- 干预后随访旨在发现局部/全身复发及潜在治疗相关后遗症,应优先采用基于风险的方法。
研究设计与样本
- 证据充足时赋予 A(高)、B(中)、C(低)证据强度以支持强、中或条件推荐;证据不足时提供临床原则和专家意见。
主要发现
- 对 <2cm 实性强化肾肿块或 predominantly 囊性 Bosniak 3-4 病变,应考虑 AS 并可能延迟干预。
- 关于 AS 的共享决策应考虑干预/竞争性死亡风险与干预的潜在肿瘤学获益。
- 讨论了肾肿块活检推荐及定期临床/影像监测的考虑。
- 干预后定义了基于风险的监测方案,包括临床/实验室评估和腹部/胸部影像,以检测局部/全身复发及可能治疗相关后遗症如进展性肾功能不全。
关键数值与推荐
- 对 <2cm 实性强化肾肿块或 Bosniak 3-4 predominantly 囊性病变考虑 AS。
- 证据强度分级:A(高)、B(中)、C(低),对应强、中或条件推荐。
- 干预后随访采用基于风险的方案,选择性使用实验室/影像资源。
临床怎么用
- 对符合条件的小肾肿块或 Bosniak 3-4 囊性病变患者,可提供 AS 并可能延迟干预。
- AS 决策应通过共享决策权衡干预风险/竞争性死亡与肿瘤学获益。
- 干预后按风险分层进行临床/实验室评估及腹部/胸部影像随访,选择性使用资源。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This AUA Guideline focuses on active surveillance (AS) and follow-up after intervention for adult patients with clinically-localized renal masses suspicious for cancer, including solid enhancing tumors and Bosniak 3/4 complex cystic lesions. MATERIALS AND METHODS: In January 2021, the Renal Mass and Localized Renal Cancer guideline underwent additional amendment based on a current literature-search. This literature search retrieved additional studies published between July 2016 to October 2020 using the same Key Questions and search criteria from the Renal Mass and Localized Renal Cancer guideline. When sufficient evidence existed, the body of evidence was assigned strength-rating of A (high), B (moderate), or C (low) for support of Strong, Moderate, or Conditional Recommendations. In the absence of sufficient evidence, additional information is provided as Clinical Principles and Expert Opinions (table 1[Table: see text]). RESULTS: AS with potential delayed intervention should be considered for patients with solid, enhancing renal masses <2cm or Bosniak 3-4 lesions that are predominantly-cystic. Shared decision-making about AS should consider risks of intervention/competing mortality versus the potential oncologic benefits of intervention. Recommendations for renal mass biopsy and considerations for periodic clinical/imaging-based surveillance are discussed. After intervention, risk-based surveillance protocols are defined incorporating clinical/laboratory evaluation and abdominal/chest imaging designed to detect local/systemic recurrences and possible treatment-related sequelae, such as progressive renal-insufficiency. CONCLUSION: AS is a potential management strategy for some patients with clinically-localized renal masses that requires careful risk-assessment, shared decision-making and periodic-reassessment. Follow-up after intervention is designed to identify local/systemic recurrences and potential treatment-related sequelae. A risk-based approach should be prioritized with selective use of laboratory/imaging resources.
引用
- Campbell SC, Uzzo RG, Karam JA, et al. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-up: AUA Guideline: Part II. J Urol. 2021. PMID: 34115531. doi:10.1097/JU.0000000000001912
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。